Biosynex sells its molecular biology business

Biosynex, based in Strasbourg, announced that it has received a binding offer from a pharmaceutical company to sell its molecular biology business. The transaction, subject to certain conditions, is expected to raise €4 million. This amount will be held in escrow during the company's safeguard proceedings. The conditions include approval by the supervising judge and the release of lienholders.

The sale includes the Ampliflash® and Ampliquick® product lines, as well as the transfer of assets and a dedicated team. Biosynex will continue to produce these products during the transition. This divestiture allows Biosynex to focus on its core businesses, such as family health and rapid testing.

CEO Larry Abensur emphasizes that this agreement will promote the technological development of the divested business and strengthen Biosynex's position in its priority markets.